Enliven Therapeutics (ELVN) Stock Forecast, Price Target & Predictions

ELVN Stock Forecast

Enliven Therapeutics stock forecast is as follows: an average price target of $39.50 (represents a 75.79% upside from ELVN’s last price of $22.47) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ELVN Price Target

The average price target for Enliven Therapeutics (ELVN) is $39.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $39.00. This represents a potential 75.79% upside from ELVN's last price of $22.47.

ELVN Analyst Ratings

Buy

According to 3 Wall Street analysts, Enliven Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ELVN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Enliven Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 15, 2024	Colleen Kusy	Robert W. Baird	$40.00	$24.05	66.32%	78.02%
Sep 23, 2024	Salim Syed	Mizuho Securities	$39.00	$23.80	63.87%	73.56%
Jun 10, 2024	Colleen Kusy	Robert W. Baird	$32.00	$22.58	41.72%	42.41%
Apr 09, 2024	Salim Syed	Mizuho Securities	$34.00	$18.30	85.79%	51.31%

The latest Enliven Therapeutics stock forecast, released on Nov 15, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $40.00, which represents a 66.32% increase from the stock price at the time of the forecast ($24.05), and a 78.02% increase from ELVN last price ($22.47).

Enliven Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	4
Avg Price Target	-	$39.50	$36.25
Last Closing Price	$22.47	$22.47	$22.47
Upside/Downside	-100.00%	75.79%	61.33%

In the current month, the average price target of Enliven Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enliven Therapeutics's last price of $22.47. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 09, 2024	H.C. Wainwright		Buy	Initialise
Aug 14, 2024	Cowen & Co.	Buy	Buy	Hold
Apr 25, 2022	SVB Leerink	Market Perform	Market Perform	Hold

Enliven Therapeutics's last stock rating was published by H.C. Wainwright on Sep 09, 2024. The company Initialise its ELVN rating from "null" to "Buy".

Enliven Therapeutics Financial Forecast

Enliven Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Enliven Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELVN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Enliven Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict ELVN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Enliven Therapeutics's previous annual EBITDA (undefined) of $NaN.

Enliven Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-26.23M	$-29.44M	$-27.39M	$-26.06M	$-24.71M	$-23.99M	$-26.44M
High Forecast	$-26.23M	$-29.44M	$-27.39M	$-26.06M	$-22.85M	$-23.99M	$-26.44M
Low Forecast	$-26.23M	$-29.44M	$-27.39M	$-26.06M	$-27.98M	$-23.99M	$-26.44M
Surprise %	-	-	-	-	-	-	-

Enliven Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELVN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Enliven Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Enliven Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ELVN last annual SG&A of $NaN (undefined).

Enliven Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-0.54	$-0.61	$-0.57	$-0.54	$-0.51	$-0.50	$-0.55
High Forecast	$-0.54	$-0.61	$-0.57	$-0.54	$-0.47	$-0.50	$-0.55
Low Forecast	$-0.54	$-0.61	$-0.57	$-0.54	$-0.58	$-0.50	$-0.55
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Enliven Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELVN previous annual EPS of $NaN (undefined).

Enliven Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IMRX	Immuneering	$1.73	$17.50	911.56%	Buy
AVTE	Aerovate Therapeutics	$2.56	$13.00	407.81%	Hold
GOSS	Gossamer Bio	$0.87	$3.75	331.03%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
CMPX	Compass Therapeutics	$1.53	$5.00	226.80%	Buy
GPCR	Structure Therapeutics	$31.48	$99.00	214.49%	Buy
CELC	Celcuity	$12.55	$39.00	210.76%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
MLTX	MoonLake Immunotherapeutics	$56.30	$100.00	77.62%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
ELVN	Enliven Therapeutics	$24.39	$39.50	61.95%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy

ELVN Forecast FAQ

Is Enliven Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Enliven Therapeutics (ELVN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ELVN's total ratings.

What is ELVN's price target?

Enliven Therapeutics (ELVN) average price target is $39.5 with a range of $39 to $40, implying a 75.79% from its last price of $22.47. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Enliven Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ELVN stock, the company can go up by 75.79% (from the last price of $22.47 to the average price target of $39.5), up by 78.02% based on the highest stock price target, and up by 73.56% based on the lowest stock price target.

Can Enliven Therapeutics stock reach $30?

ELVN's average twelve months analyst stock price target of $39.5 supports the claim that Enliven Therapeutics can reach $30 in the near future.

What are Enliven Therapeutics's analysts' financial forecasts?

Enliven Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.14M (high $-73.275M, low $-78.404M), average SG&A $0 (high $0, low $0), and average EPS is $-1.559 (high $-1.52, low $-1.627). ELVN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-109M (high $-109M, low $-109M), average SG&A $0 (high $0, low $0), and average EPS is $-2.261 (high $-2.261, low $-2.261).